Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 25, 2018

Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005)

Ludwig Kappos, Krzysztof Selmaj, Amit Bar-Or, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalbán, Eva Havrdová, James Sheffield, Kartik Raghupathi, Bruce Cree, Jeffrey Cohen
First published April 9, 2018,
Ludwig Kappos
1University Hospital and University of Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krzysztof Selmaj
2Medical University of Lodz Lodz Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Bar-Or
3Center for Neuroinflammation and Therapeutics, and Multiple Sclerosis Division, University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giancarlo Comi
4San Raffaele Scientific Institute, Vita-Salute San Raffaele University Milan Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas Arnold
5NeuroRx Research and Montréal Neurological Institute, McGill University Montreal QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Steinman
6Beckman Center for Molecular Medicine, Stanford University Medical Center Stanford CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Peter Hartung
7Heinrich-Heine University Dusseldorf Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Montalbán
8University of Toronto, St Michael’s Hospital Toronto ON Canada
9Cemcat, Vall d’Hebron Hospital, Universitat Autonoma Barcelona Toronto ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Havrdová
10First Medical Faculty, Charles University Prague Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Sheffield
11Receptos, a wholly owned subsidiary of Celgene San Diego CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kartik Raghupathi
11Receptos, a wholly owned subsidiary of Celgene San Diego CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Cree
12UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Cohen
13Mellen Center for MS Treatment and Research, Cleveland Clinic Cleveland OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005)
Ludwig Kappos, Krzysztof Selmaj, Amit Bar-Or, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalbán, Eva Havrdová, James Sheffield, Kartik Raghupathi, Bruce Cree, Jeffrey Cohen
Neurology Apr 2018, 90 (15 Supplement) S36.005;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Article Information

vol. 90 no. 15 Supplement S36.005

Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 9, 2018.

Copyright & Usage: 
© 2018

Author Disclosures

    1. Ludwig Kappos1,
    2. Krzysztof Selmaj2,
    3. Amit Bar-Or3,
    4. Giancarlo Comi4,
    5. Douglas Arnold5,
    6. Lawrence Steinman6,
    7. Hans-Peter Hartung7,
    8. Xavier Montalbán8,9,
    9. Eva Havrdová10,
    10. James Sheffield11,
    11. Kartik Raghupathi11,
    12. Bruce Cree12 and
    13. Jeffrey Cohen13
  1. Ludwig Kappos1,
  2. Krzysztof Selmaj2,
  3. Amit Bar-Or3,
  4. Giancarlo Comi4,
  5. Douglas Arnold5,
  6. Lawrence Steinman6,
  7. Hans-Peter Hartung7,
  8. Xavier Montalbán8,9,
  9. Eva Havrdová10,
  10. James Sheffield11,
  11. Kartik Raghupathi11,
  12. Bruce Cree12 and
  13. Jeffrey Cohen13
  1. 1University Hospital and University of Basel Basel Switzerland
  2. 2Medical University of Lodz Lodz Poland
  3. 3Center for Neuroinflammation and Therapeutics, and Multiple Sclerosis Division, University of Pennsylvania Philadelphia PA United States
  4. 4San Raffaele Scientific Institute, Vita-Salute San Raffaele University Milan Italy
  5. 5NeuroRx Research and Montréal Neurological Institute, McGill University Montreal QC Canada
  6. 6Beckman Center for Molecular Medicine, Stanford University Medical Center Stanford CA United States
  7. 7Heinrich-Heine University Dusseldorf Germany
  8. 8University of Toronto, St Michael’s Hospital Toronto ON Canada
  9. 9Cemcat, Vall d’Hebron Hospital, Universitat Autonoma Barcelona Toronto ON Canada
  10. 10First Medical Faculty, Charles University Prague Czech Republic
  11. 11Receptos, a wholly owned subsidiary of Celgene San Diego CA United States
  12. 12UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco San Francisco CA United States
  13. 13Mellen Center for MS Treatment and Research, Cleveland Clinic Cleveland OH United States

Article usage

Article usage: April 2018 to April 2022

AbstractFullPdfSource
Apr 20186400Highwire
May 20183500Highwire
Jun 20184100Highwire
Jul 20182300Highwire
Aug 20182900Highwire
Sep 2018800Highwire
Oct 20181300Highwire
Nov 20183200Highwire
Dec 20182200Highwire
Jan 20192200Highwire
Feb 20191900Highwire
Mar 20191600Highwire
Apr 20192100Highwire
May 2019800Highwire
Jun 2019500Highwire
Jul 2019500Highwire
Aug 2019700Highwire
Sep 2019500Highwire
Oct 2019400Highwire
Nov 2019500Highwire
Dec 2019500Highwire
Jan 2020900Highwire
Feb 2020300Highwire
Mar 2020500Highwire
Apr 2020300Highwire
May 2020100Highwire
Jun 2020200Highwire
Aug 2020200Highwire
Sep 2020400Highwire
Oct 2020900Highwire
Nov 2020500Highwire
Dec 20202700Highwire
Jan 2021400Highwire
Feb 2021300Highwire
Mar 2021300Highwire
Apr 2021700Highwire
May 2021100Highwire
Jun 2021200Highwire
Jul 2021200Highwire
Aug 2021200Highwire
Sep 2021200Highwire
Oct 2021200Highwire
Nov 2021200Highwire
Jan 2022300Highwire
Feb 2022200Highwire
Mar 2022600Highwire
Apr 2022100Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise